<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158072">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01896193</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-334-0119</org_study_id>
    <nct_id>NCT01896193</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection</brief_title>
  <official_title>A Phase 3b, Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness and safety of sofosbuvir plus
      ribavirin administered for 16 weeks and 24 weeks in patients with chronic genotype 1 (GT1)
      or genotype 3 (GT3) HCV infection.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of treatment (SVR12)</measure>
    <time_frame>Posttreatment Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>SVR12 is defined as HCV RNA &lt; the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Any adverse event leading to permanent discontinuation of study drug(s)</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with sustained virologic response at 4 and 24 weeks after discontinuation of treatment (SVR4 and SVR24)</measure>
    <time_frame>Posttreatment Weeks 4 and 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>SVR4 and SVR24 is defined as HCV RNA &lt; the lower limit of quantitation (LLOQ) 4 weeks and 24 weeks following the last dose of study drug, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with on-treatment virologic failure and relapse</measure>
    <time_frame>Baseline to posttreatment Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>On-treatment virologic failure is defined as either:
Breakthrough: HCV RNA ≥ LLOQ after having previously had HCV RNA &lt; LLOQ, while on treatment, confirmed with 2 consecutive values (note: second confirmation value can be posttreatment), or last available on-treatment measurement with no subsequent follow-up values, OR
Rebound: &gt; 1 log10IU/mL increase in HCV RNA from nadir while on treatment, confirmed with 2 consecutive values (note: second confirmation value can be posttreatment), or last available on-treatment measurement with no subsequent follow-up values, OR
Nonresponse: HCV RNA persistently ≥ LLOQ through 8 weeks of treatment
Relapse is defined as:
HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA &lt; LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Sofosbuvir+ribavirin 16 weeks GT1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with chronic genotype 1 HCV infection will receive sofosbuvir plus ribavirin for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sofosbuvir+ribavirin 24 weeks GT1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with chronic genotype 1 HCV infection will receive sofosbuvir plus ribavirin for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sofosbuvir+ribavirin 16 weeks GT3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with chronic genotype 3 HCV infection will receive sofosbuvir plus ribavirin for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sofosbuvir+ribavirin 24 weeks GT3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with chronic genotype 3 HCV infection will receive sofosbuvir plus ribavirin for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir</intervention_name>
    <description>Sofosbuvir 400 mg tablet administered orally once daily</description>
    <arm_group_label>Sofosbuvir+ribavirin 16 weeks GT1</arm_group_label>
    <arm_group_label>Sofosbuvir+ribavirin 24 weeks GT1</arm_group_label>
    <arm_group_label>Sofosbuvir+ribavirin 16 weeks GT3</arm_group_label>
    <arm_group_label>Sofosbuvir+ribavirin 24 weeks GT3</arm_group_label>
    <other_name>Sovaldi®</other_name>
    <other_name>PSI-7977</other_name>
    <other_name>GS-7977</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Ribavirin 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)</description>
    <arm_group_label>Sofosbuvir+ribavirin 16 weeks GT1</arm_group_label>
    <arm_group_label>Sofosbuvir+ribavirin 24 weeks GT1</arm_group_label>
    <arm_group_label>Sofosbuvir+ribavirin 16 weeks GT3</arm_group_label>
    <arm_group_label>Sofosbuvir+ribavirin 24 weeks GT3</arm_group_label>
    <other_name>RBV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed chronic genotype 1 or 3 HCV infection.

          -  HCV treatment-naïve.

          -  Subjects will have cirrhosis status assessment; liver biopsy may be required.

          -  Screening laboratory values within predefined thresholds.

          -  Use of two effective contraception methods if female of childbearing potential or
             sexually active male.

        Exclusion Criteria:

          -  Pregnant or nursing female or male with pregnant female partner.

          -  Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV).

          -  Contraindication to ribavirin therapy.

          -  Excessive alcohol ingestion as defined by protocol.

          -  History of solid organ transplantation.

          -  Current or prior history of clinical hepatic decompensation.

          -  History of clinically significant illness or any other medical disorder that may
             interfere with subject treatment, assessment or compliance with the protocol.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathryn Kersey, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Nutrition of Academy of Sciences</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institution of High Professional Education First Moscow State Medical University</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Scientific Research Institution of Gastroenterology of Moscow Healthcare Department</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institution of Healthcare of Sverdlovsk Region</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital 24</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Scientific and Research Institute of Epidemiology of Rospotrebnadzor</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Diagnostics and Research Center of Federal Bedgetary Institution</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krasnoyarsk Regional Center for Prevention and Control of AIDS and Infectious Diseases</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Research Institution of Emergency Care n.a. N.V. Sclifosovskiy of Moscow</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital of the Russian Academy of Sciences</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institution of Tumen Region</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavropol State Medical University of Ministry of Healthcare</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Clinical Hospital No. 1</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg Center for Prevention and Control of AIDS and Infectious Diseases</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Military Academy n.a. S.M. Kirov</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Company Hepatolog</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 25, 2014</lastchanged_date>
  <firstreceived_date>July 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
